NovoCure/$NVCR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NovoCure
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- Ticker
- $NVCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,605
- Headquarters
- Baar, Switzerland
- Website
- www.novocure.com
NovoCure Metrics
BasicAdvanced
$1.6B
-
-$1.06
1.08
-
Price and volume
Market cap
$1.6B
Beta
1.08
52-week high
$21.45
52-week low
$9.82
Average daily volume
1.8M
Financial strength
Current ratio
2.488
Quick ratio
2.301
Long term debt to equity
0.589
Total debt to equity
0.66
Interest coverage (TTM)
-4.30%
Profitability
EBITDA (TTM)
-103.49
Gross margin (TTM)
77.25%
Net profit margin (TTM)
-16.78%
Operating margin (TTM)
-16.41%
Effective tax rate (TTM)
6.75%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-6.79%
Return on equity (TTM)
-35.18%
Valuation
Price to revenue (TTM)
2.102
Price to book
4.26
Price to tangible book (TTM)
4.26
Price to free cash flow (TTM)
-61.951
Free cash flow yield (TTM)
-1.61%
Free cash flow per share (TTM)
-0.214
Growth
Revenue change (TTM)
12.94%
Earnings per share change (TTM)
-34.03%
3-year revenue growth (CAGR)
12.91%
10-year revenue growth (CAGR)
27.28%
3-year earnings per share growth (CAGR)
-17.12%
10-year earnings per share growth (CAGR)
-4.51%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
Analyst projections of the future price of NovoCure stock.
Bulls say / Bears say
Third-quarter revenue rose 16% year on year as active patients grew 19%, and NovoCure raised its full-year revenue and adjusted EBITDA guidance. That points to stronger commercial momentum and a path towards sustained profitability. (NovoCure)
Japan approved Optune Pax for locally advanced pancreatic cancer, adding a major market for the new product. The approval was based on Phase 3 results showing a statistically significant improvement in overall survival and delayed pain progression when it was added to chemotherapy. (NovoCure)
The Phase 3 TRIDENT study failed to show a survival advantage from starting TTFields earlier in newly diagnosed glioblastoma. This weakens one route to expanding the established Optune franchise. (Endpoints News)
The Optune Pax launch faces a practical hurdle: NovoCure said the new competing pancreatic-cancer drug daraxonrasib has limited its access to US practices, and US active patients fell from 285 in the second quarter to 266 in the third. (Yahoo Finance)
NovoCure remains loss-making on a GAAP basis, with a $97.2 million net loss in the first nine months of 2026. The company also warns that operating expenses may outpace gross profit as it expands into new indications. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
Upcoming events
No upcoming events
NovoCure News
AllArticlesVideos
Funds containing NovoCure
Fund name | Fund size | $NVCR weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.14% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.14% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.14% |
iShares Ageing Population$AGED | $953M | 0.13% |
iShares Ageing Population£AGES | $953M | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.